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Abstract
The role of inﬂuenza vaccination in patients suffering from autoimmune diseases, including systemic lupus erythematosus
(SLE) and rheumatoid arthritis (RA), has long been a subject of discussion. The risk of exacerbation of the main disease
following vaccination is of particular concern, and needs to be carefully evaluated against the risk of disease ﬂares as a result of
infections. Our study included 69 SLE patients and 54 RA patients, all in stable condition. We split the groups into two
subgroups each: patients in SLE1 (23 patients) and RA1 (23 patients) received the ﬂu vaccine (“Vaxigrip”, Aventis Pasteur) in
November2003. Patients in SLE2 (46patients) and RA2 (31patients) werenot vaccinated. Throughout the following year, we
studied parameters of disease activity and the occurrence of viral respiratory and bacterial infections in our patients. The
vaccine was well tolerated in all cases. Vaccinated patients had signiﬁcantly fewer occurrences of infections. Every viral and
bacterial infection resulted in the worsening of the main disease. We believe that inﬂuenza vaccine is indicated for SLE and RA
patients in stable condition. However, this decision must be made on a patient-by-patient basis. We plan to continue our study
with the goal of formulating a better protocole for the clinical practice.
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Introduction
Vaccination against inﬂuenza is the primary strategy to
reduce the mortality and morbidity associated with
inﬂuenza. The vaccine is primarily recommended for
persons at increased risk of severe inﬂuenza such as
immunocompromised subjects, including patients
with autoimmune diseases (Herron et al. 1979;
Shoenfeld and Rose 2004).
Theroleofinﬂuenzavaccinationinpatientssuffering
from autoimmune diseases, including systemic lupus
erythematosus (SLE) and rheumatoid arthritis (RA),
has long been a subject of discussion (Nosal 2000).
Etiology of autoimmune diseases is still unknown, and
among others, two possible triggers are cited in the
literature: infections and vaccination (Rose 1998;
Sibilia and Maillefert 2002; Aron-Maor and Shoenfeld
2004). An infection can induce or trigger autoimmune
disease (Doran et al. 2002; Glu ¨ck et al. 2005).
Viral infections have speciﬁcally been causally asso-
ciated with SLE (Zandman-Goddard and Shoenfeld
2004), and there are documented cases of SLE
presenting itself after vaccination (Shoenfeld and
Rose 2004). However, it has also been documented
thattheswine-ﬂuinﬂuenzavaccinewaswelltoleratedin
SLE and RA patients (Avery 1999; Stojanovich 2005;
Del Porto et al. 2006), albeit with a lower response to
immunization compared to healthy controls.
However, same case reports suggest an association
between inﬂuenza vaccination and the development
or exacerbation of chronic autoimmune disorders
such as RA, SLE (Blumberg et al. 1980) and vasculitis
(Iyngkaran et al. 2003).
Patients with autoimmune rheumatic diseases run
twice as high a risk of infection compared to healthy
controls (Doran et al. 2002). This is due in part to
the immunoregulatory abnormalities associated with
the disease itself, but also in large part to the
immunosuppressive therapy administered to these
patients in the interest of delaying joint destruction.
The effect of disease-modifying therapies on the
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some of the more aggressive protocols are adminis-
tered that may lead to opportunistic infections
otherwise only seen in patients with advanced HIV
infection (Glu ¨ck et al. 2005).
Materials and methods
Our study included 69 patients with SLE (mean age
44.74 ^ 13.58) and 54 patients with RA (mean age
57.78 ^ 12.42). We further split both groups into
two subgroups each: subgroups SLE1 (23 patients,
33.33%) and RA1 (23 patients, 42.59%) included
patients with SLE and RA, respectively, who received
the ﬂu vaccine (“Vaxigrip”, Aventis Pasteur).
Subgroups SLE2 (46 patients, 66.67%) and RA2
(31 patients, 57.41%) were comprised of patients
who were not vaccinated against ﬂu. The two pairs
of subgroups were comparable with respect to age,
gender, disease activity, manifestations of the main
disease, and other parameters (such as immuno-
serological parameters, etc). Patients from groups
SLE1 and RA1 were all vaccinated in November 2003.
Throughout the following year, we studied parameters
of disease activity (SLEDAI for SLE) and the
occurrence of viral respiratory and bacterial infections
in our patients.
Results
The vaccine waswell tolerated byall patients in groups
SLE1 and RA1. The following occurrences of viral
respiratory and bacterial infections were registered in
our patients: 1 (2.17%) patient from SLE2 had
pneumonia; 2 (8.7%) patients from SLE1 and 17
(36.97%) patients from SLE2 suffered from acute
bronchitis that required antibiotic treatment. Various
viral respiratory infections occurred signiﬁcantly more
often in SLE2 compared to SLE1, with p , 0.005.
However, these infections also correlated with age
(patients older than 30 years of age) with p ¼ 0.04783.
The occurrence of bacterial and viral respiratory
infections in our SLE population is summarized in
Table I. In no single case did we witness worsening
of main disease after vaccination. Unfortunately, this
was not the case in SLE2, where primary symptoms of
SLE worsened after treatments of viral and bacterial
infections with statistical signiﬁcance (p ¼ 0.008).
A similar tendency was registered in patients with RA.
No pneumonia occurred in either RA1 or RA2.
However, acute bronchitis that required antibiotic
treatment was diagnosed in only 1 (4.35%) patient
in RA1, compared to 7 (22.58%) patients in RA2.
Various viral respiratory infections were seen in 2
(8.70%) patients in RA1, compared to 19 (61.29%)
patients in RA2, a statistically signiﬁcant difference
(Table II). Every viral and bacterial infection in
our autoimmune patients diseases resulted in the
worsening of the main disease, and required a
correction of immune-suppressants.
Discussion
It is important to note that infections are of particular
concern to autoimmune patients (Shoenfeld and Rose
2004). Not only is the course of the main disease often
aversely affected by the infection, but also cytostatic
therapy has to be paused during that time, which
may itself lead to exacerbation of the main disease
(Fomin et al. 2006). To make matters worse,
autoimmune patients receive long-term treatment
with steroids and immunosuppressant, which makes
them more susceptible to infections such as inﬂuenza.
The goal of our study is two-fold. On the one hand,
we study the risks associated with vaccination by a
modern inﬂuenza vaccine in SLE and RA patients in
stable condition. Additionally, we analyse the dangers
posed by viral respiratory and bacterial infections to
these patients.
We have shown that vaccination against inﬂuenza
was safe and generated a good humoral response in
SLE and RA.
Although yearly inﬂuenza vaccination is now
recommended for patients with RA, a paucity of
long-term studies deal with the inﬂuence of repeated
vaccination upon both the incidence and exacerbation
of pre-existing systemic rheumatic diseases (Kurland
et al. 1984; Gavaghan and Webber 1993). If a true
increase in relative risk exists, albeit small, then an
increased frequency of such complications might be
anticipated. Although for the vast majority of patients
the beneﬁts of regular inﬂuenza vaccination will likely
far exceed its potential risks, westill advise appropriate
monitoring of individuals with known systemic
rheumatic diseases, early reporting of suspected
adverse events associated with vaccination, and
consideration of large prospectivestudies to determine
the actual risks of currently recommended vaccination
protocols (Chalmers et al. 1994; Cimmino et al. 1995;
Avery 1999).
Table I. Systemic lupus erythematosus (SLE).
SLE1 SLE2
Disease N (%) N (%) p
Pneumonia 0(0) 1(8.7) ,0.05
Acute bronchitis 1(4.3) 17(36.9) ,0.05
Viral respiratory infections 5(21.7) 21(45.6) ,0.05
Table II. Rheumatoid arthritis (RA).
RA1 RA2
Disease N (%) N (%) p
Pneumonia 0(0) 0(0) 0
Acute bronchitis 1(4.3) 7(22.6) ,0.05
Viral respiratory infections 2(8.7) 19(61.3) ,0.05
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vaccination in autoimmune patients is still sub-
optimal, mostly because the patients have not been
offered the vaccine. Reduced compliance with
immunization against inﬂuenza is related to concerns
about the vaccine’s safety for these patients. Our
presentresultsverifythesafetyofinﬂuenzavaccination
in rheumatoid arthritis, conﬁrming our own and other
previous studies in SLE and RA, where patients did
not experience signiﬁcant clinical ﬂares following
vaccination.
The assessment of efﬁcacy and safety of vaccination
against the inﬂuenza virus in patients with rheumatoid
arthritis must place special emphasis on the effect of
disease-modifying anti-rheumatic drugs (DMARDs)
such as tumor necrosis factor (TNF) blockers. The
humoral response to inﬂuenza vaccination is not
affected by the use ofprednisone or DMARDs (Fomin
et al. 2006).
Our study indicates that a modern inﬂuenza vaccine
is well tolerated in SLE and RA patients in stable
condition: in no single case was there a worsening of
the main disease after immunization. Furthermore,
we concluded that the patients run a much higher risk
of disease exacerbation as a result of viral or bacterial
infections if not vaccinated.
Conclusions
We believe that inﬂuenza vaccine is indicated for
SLE and RA patients in stable condition. However,
this decision has to be made individually, on a patient-
by-patient basis. We plan to continue our study with
the goal of formulating a better protocol for clinical
practice.
References
Aron-Maor A, Shoenfeld Y. 2004. Vaccination and autoimmunity.
In: Shoenfeld Y, Rose NR, editors. Infection and autoimmunity.
New York, NY: Elsevier BV. p 105–116.
Avery RK. 1999. Vaccination of the immunosuppressed adult
patient with rheumatologic disease. Rheum Dis Clin North Am
25:567–584.
Blumberg S, Bienfang D, Kantrowitz FG. 1980. A possible
association between inﬂuenza vaccination and small-vessel
vasculitis. Arch Intern Med 140:847–848.
Chalmers A, Scheifele D, Patterson C, Williams D, Weber J,
Shuckett R, et al. 1994. Immunization of patients with
rheumatoid arthritis against inﬂuenza: A study of vaccine safety
and immunogenicity. J Rheumatol 21:1203–1206.
Cimmino MA, Seriolo B, Accardo S. 1995. Inﬂuenza vaccination in
rheumatoid arthritis. J Rheumatol 22:1802–1803.
Gavaghan T, Webber CK. 1993. Severe systemic vasculitic
syndrome post inﬂuenza vaccination. Aust NZ J Med 23:220.
Del Porto F, Lagana ` B, Biselli R, Donatelli I, Campitelli L, Nisini R,
et al. 2006. Inﬂuenza vaccine administration in patients with
systemic lupus erythematosus and rheumatoid arthritis: Safety
and immunogenic. Vaccine 24(16):3217–3223.
Doran MF, Crowson CS, Pond GR, O’Fallon M, Gabriel SE. 2002.
Frequency of infection in patients with rheumatoid arthritis
compared with controls. A population based study. Arthritis
Rheum 46:2287–2293.
Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, et al.
2006. Vaccination against inﬂuenza in rheumatoid arthritis: The
effectofdiseasemodifyingdrugs,includingTNFa blockers.Ann
Rheum Dis 65:191–194.
Glu ¨ck T, Kiefmann B, Grohmann M, Falk W, Straub RH,
Scholmerich J. 2005. Immune status and risk for infection
in patients receiving chronic immunosuppressive therapy.
Rheumatol 32:1473–1480.
Herron A, Dettleff G, Hixon B, Brandwin L, Ortbals D, Hornick R,
et al. 1979. Inﬂuenza vaccination in patients with rheumatic
diseases: Safety and efﬁcacy. JAMA 242:53–56.
Iyngkaran P, Limaye V, Hill G, Henderson D, Pile KD,
Rischmueller M. 2003. Rheumatoid vasculitis following inﬂu-
enza vaccination. Rheumatology 42:907–909.
Kurland LT, Molgaard CA, Kurland EM, Erdtmann FJ, Stebbing
GET. 1984. Lack of association of swine ﬂu vaccine and
rheumatoid arthritis. Mayo Clin Proc 59:816–821.
Nosal GJV. 2000. Vaccination and autoimmunity. J Autoimmun
14:15–22.
Rose NR. 1998. The role of infection in the pathogenesis of
autoimmune disease. Semin Immunol 10(1):5–13.
Shoenfeld Y, Rose NR, editors. 2004. Infection and autoimmunity.
New York, NY: Elsevier BV. p 747.
Sibilia J, Maillefert JF. 2002. Vaccination and rheumatoid arthritis.
Ann Rheum Dis 61:575–576.
Stojanovich L. 2005. Inﬂuenza vaccination of patients with systemic
lupus erythematosus (SLE) and rheumatoid arthritis (RA)
Abstract book in: VIAMR, Conference, session 2; Oct;
Lausanne (CD). p 26–28.
Zandman-Goddard G, Shoenfeld Y. 2004. SLE and Infections.
In: Shoenfeld Y, Rose NR, editors. Infection and autoimmunity.
New York, NY: Elsevier BV. p 1491–1503.
Flu vaccination of SLE and RA patients 375